RSV and hMPV combination vaccine study for adults
Part of Lungs & breathing clinical trials.
This study tests a new vaccine that may protect against two common viruses that cause breathing problems, RSV and hMPV. It is for healthy younger adults (18-49) and older adults (60-80) to see if the vaccine is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are either between 18 and 49 years old or between 60 and 80 years old.
- You are generally healthy or have stable medical conditions (for older adults).
- Your body mass index (BMI) is between 18 and 33.
- You have not had a confirmed RSV or hMPV infection in the past year.
- You have not received a vaccine for RSV or hMPV before, and you are not taking immune-suppressing medications.
- For women who can get pregnant: you must use two effective birth control methods and have negative pregnancy tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new vaccine that targets two respiratory viruses, RSV and HMPV, to see if it's safe and effective in adults 60 years and older. It may help prevent serious lung infections caused by these viruses.
This study tests a new vaccine that protects against two common respiratory viruses: RSV and HMPV. It aims to see if the vaccine is safe and works well in older adults, who are at higher risk for serious illness from these viruses.
This study tests a new vaccine to protect against RSV (a common respiratory virus that causes cold-like illness, especially serious in older adults). The vaccine is made in laboratory cell cultures and includes an immune-boosting ingredient. Researchers want to see if it's safe and if it helps your body fight RSV infection.
This trial tests an experimental vaccine for respiratory syncytial virus (RSV), a common virus that can cause serious lung infections, especially in older adults. The study checks if the vaccine is safe and how the body responds to it.
This study tests an experimental vaccine to see if it is safe for healthy adults. The vaccine is made with mRNA technology and aims to protect against RSV, a common respiratory virus.
This trial tests a new mRNA vaccine designed to protect older adults against two common respiratory viruses, RSV and hMPV. It aims to see if the vaccine is safe and creates a good immune response.
Hear when a new Respiratory Syncytial Virus Infections+Metapneumovirus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.